Fundatur principium competitive ligaturae
Copia ut packaged in pera signato temperatus (4-30℃ vel 40-86℉)
Fluxus lateralis chromatographicus immunoassay
Qualitative deprehensio celeri test ornamentum AMRDT110
Deprehensio qualitativa celeri experimenti ornamentum AMRDT110 est fluxus chromatographicus lateralis immunoassay pro detectione qualitativa multiplicium medicamentorum et metabolitarum medicamentorum in urinis ad sequentes collectiones abscissas;
| Test | Calibrator | Abscise (ng/mL) |
| Amphetamine (AMP1000) | D-Amphetamine | 1,000 |
| Amphetamine (AMP500) | D-Amphetamine | 500 |
| Amphetamine (AMP300) | D-Amphetamine | 300 |
| Benzodiazepines (BZO300) | Oxazepam | 300 |
| Benzodiazepines (BZO200) | Oxazepam | 200 |
| Barbiturates (BAR) | Secobarbital | 300 |
| Buprenorphine (BUP) | Buprenorphine | 10 |
| COCAINUM (COC) | Benzoylecgnine | 300 |
| Cotinine (COT) | Cotinine | 200 |
| Methadone metabolite (EDDP) | 2-Ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine | 100 |
| Fentanyl (FYL) | Fentanyl | 200 |
| Ketamine (KET) | Ketamine | 1,000 |
| Synthetica Cannabinoidea (K2 50) | JWH-018 acidum 5-pentanoicum/JWH-073 4-acidi butanoicum | 50 |
| Synthetica Cannabinoidea (K2 200) | JWH-018 acidum 5-pentanoicum/JWH-073 4-acidi butanoicum | 200 |
| Methamphetamine (mAMP1000/ MET1000) | D-Methamphetamine | 1,000 |
| Methamphetamine (mAMP500/ MET500) | D-Methamphetamine | 500 |
| Methamphetamine (mAMP300/ MET300) | D-Methamphetamine | 300 |
| Methylenedioxymethamphetamine (MDMA) | D,L-Methylenedioxymethamphetamine | 500 |
| Morphine (MOP300/OPI300) | Morphine | 300 |
| Methadone (MTD) | Methadone | 300 |
| Methaqualone (MQL) | Methaqualone | 300 |
| Opiates (OPI 2000) | Morphine | 2,000 |
| Oxycodone (OXY) | Oxycodone | 100 |
| Phencyclidine (PCP) | Phencyclidine | 25 |
| Propoxyphene (PPX) | Propoxyphene | 300 |
| Antidepressants tricyclic (TCA) | Nortriptyline | 1,000 |
| Marijuana (THC) | 11-nec-9-THC-9-COOH | 50 |
| Tramadol (TRA) | Tramadol | 200 |
Configurationes detectionis Qualitativae rapidae test ornamentum AMRDT110 ex omni compositione medicamentorum analytarum inscriptarum consistere possunt.
Deprehensio Qualitativa celeri experimentum AMRDT110 est immunoassay innixa principio vincendi competitive.Medicamenta, quae in specimine urinae adesse possunt, contendunt contra suum proprium medicamentum conjugatum pro locis ligandis in proprio anticorpore.
In probatione urina speciminis sursum migrat per actionem capillarem.Medicamentum, si in specimine urinae sub intentione eius abscise inest, situs ligaturae specificae anticorporis non saturabit.Anticorpus tunc agere faciet cum interdum pharmacopola conjugato et linea visibili colorata ostendet in regione probata lineae speciei pharmaci habenae.Praesentia medicamentorum supra intentionem abscissorum omnes situs ligaturae anticorporis saturabit.Ergo linea colorata non formabit in regione recta probata.
Specimen urinae medicamento-positivae non generabit lineam coloratam in regione lineae probatae speciei habenae propter medicamentorum competitions, dum speciminis urinae negativae pharmacopolam generabit lineam in regione recta probata propter absentiam pharmaci competition.
Ut pro potestate processualis servetur, linea colorata semper in regione ditionis lineae apparebit, indicans volumen proprium speciminis additum esse et membranam wicking incidisse.
